目 录 | | | | 二、财务报表……………………………………………………… 第 7—14 | | | 页 | | --- | --- | --- | --- | | （一）合并资产负债表…………………………………………… | 第 | 7 | 页 | | （二）母公司资产负债表………………………………………… | 第 | 8 | 页 | | （三）合并利润表………………………………………………… | 第 | 9 | 页 | | （四）母公司利润表………………………………………………第 | | 10 | 页 | | （五）合并现金流量表……………………………………………第 | | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | | 14 | 页 | | | | 审 计 报 告 天健审〔2025〕6565 号 江苏辉丰生物农业股份有限公司全体股东： 一、审计意见 我们提醒财务报表使用者关注，如财务报表附 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—4 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕6567 号 江苏辉丰生物农业股份有限公司全体股东： 我们接受委托，审计了江苏辉丰生物农业股份有限公司（以下简称辉丰股份 公司）2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表， 2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所 有者权益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审 计了后附的辉丰股份公司管理层编制的 2024 年度《非经营性资金占用及其他关 联资金往来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供辉丰股份公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为辉丰股份公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解辉丰股份公司 2024 年度非经营性资金占用及其他关联资金 往 ...

江苏辉丰生物农业股份有限公司独立董事关于 第九届董事会第八次会议有关事项的独立意见 根据《公司法》、《证券法》、《上市公司独立董事管理办法》、《深圳证 券交易所股票上市规则》和《公司章程》等有关规定，作为江苏辉丰生物农业股 份有限公司(以下称"公司")的独立董事，我们对第九届董事会第八次会议相关 事项发表如下独立意见： 五、关于子公司开展套期保值业务的独立意见 一、对公司关联方资金占用和对外担保情况的独立意见 1、我们对报告期内实际控制人及其它关联方占用资金情况进行了核查和监 督，认为报告期内公司控股股东、实际控制人或其他关联方没有直接或变相占用 公司资金。 2、截至2024年12月31日，公司没有为控股股东、实际控制人以及其他关联 方提供担保。 二、关于2024年度利润分配预案的独立意见 2024年利润分配预案符合公司法和公司章程的相关规定，不存在侵害中小股 东权益的情形。我们同意公司2024年度利润分配方案，并同意提交公司2024年年 度股东大会审议。 三、关于内部控制自我评价报告的独立意见 我们认为：公司已根据有关法律、法规和证券监管部门的要求建立健全了 内部控制制度，并于2024年度得到了执行，在经营 ...

江苏辉丰生物农业股份有限公司 董事会对独立董事独立性评估的专项意见 经核查独立董事李昌莲、花荣军、杨兆全的任职经历以及签署的相关自查文 件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进 行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上市公司独 立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市 公司规范运作》中对独立董事独立性的相关要求。 江苏辉丰生物农业股份有限公司董事会 2025 年 4 月 20 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等要求，江苏辉丰生物农业股份有限公司（以下简称"公司"） 董事会，就公司在任独立董事李昌莲、花荣军、杨兆全的独立性情况进行评估并 出具如下专项意见： ...

江苏辉丰生物农业股份有限公司 独立董事2024年度述职报告 （李昌莲） 本人作为江苏辉丰生物农业股份有限公司（以下简称"公司"）的独 立董事，严格按照《公司法》、《证券法》、《国务院办公厅关于上市公 司独立董事制度改革的意见》、《上市公司治理准则》、《上市公司独立 董事管理办法》以及深圳证券交易所业务规则等相关法律法规和规章制度 的规定，以及《公司章程》、公司《独立董事制度》的相关规定和要求， 秉持客观、公正、独立的原则，勤勉尽责，忠实履行职务，积极出席相关 会议，充分发挥独立董事的作用，认真审议董事会各项议案，切实维护公 司和全体股东的利益。现将本人2024年度的工作情况作汇报如下： 一、本人基本情况 1 项和其他重大事项均履行了相关程序，合法有效。本人对公司董事会审议 的各项议案均投了赞成票，没有提出异议。 2024年度，本人出席董事会的情况如下： 1、对各次董事会会议审议的相关议案均投了赞成票； 李昌莲，女，1969 年出生，中国国籍，无境外永久居留权，中国注册会 计师、高级会计师。南通总会计师学会常务理事，江苏省注册会计师协会理 事。曾任江苏必康制药股份有限公司、江苏爱朋医疗科技股份有限公司和江 苏海 ...

一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 21476.88万股，累计占流通股比： 18.19%，较上期变化： -5786.94万股。 | 名称 | 持有数量(万股) | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 张宏德 | 5092.79 | 4.31 | 不变 | | 仲汉根 | 3942.16 | 3.34 | -6893.42 | | 苏仕 | 3245.00 | 2.75 | 0.40 | | 江苏辉丰生物农业股份有限公司-第一期员工持股 计划 | 3059.53 | 2.59 | 不变 | | 高文新 | 2086.73 | 1.77 | 新进 | | 唐中义 | 1260.66 | 1.07 | 不变 | | 黄菊妹 | 835.00 | 0.71 | -156.26 | | 刘军 | 761.42 | 0.64 | 不变 | | 彭崇乾 | 610.00 | 0.52 | 不变 | | 张海忠 | 583.59 | 0.49 | 63.51 | | | 较上个报告期 ...

Financial Performance - The company's revenue for Q1 2025 was ¥74,023,205, representing a 29.37% increase compared to ¥57,219,935 in the same period last year[5] - Net profit attributable to shareholders decreased by 67.63% to ¥15,658,160 from ¥48,376,333 in the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥11,728,221, a significant increase of 231.40% from a loss of ¥8,925,396 in the same period last year[5] - Total operating revenue for the current period reached ¥74,023,205, an increase of 29.3% compared to ¥57,219,935 in the previous period[30] - Net profit for the current period was ¥14,540,840.10, a decrease of 70.4% from ¥49,105,740.28 in the previous period[30] - Operating profit decreased to ¥14,445,849.48, down 70.9% from ¥49,579,678.23 in the previous period[30] Cash Flow and Assets - Operating cash flow improved dramatically, reaching ¥14,860,294, up 308.05% from a negative cash flow of ¥7,142,715 in the previous year[5] - Cash flow from operating activities generated a net amount of ¥14,860,293.57, compared to a negative cash flow of ¥7,142,715.43 in the previous period[33] - Cash and cash equivalents at the end of the period totaled ¥34,028,948.41, an increase from ¥31,613,307.56 at the end of the previous period[35] - Total assets increased by 3.64% to ¥2,357,032,165 from ¥2,274,291,204 at the end of the previous year[5] - The company reported a total current asset balance of ¥371,397,743.85 as of March 31, 2025, an increase from ¥327,608,144.44 at the beginning of the period[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,086[9] - The company's basic earnings per share decreased by 67.60% to ¥0.0104 from ¥0.0321 in the same period last year[5] - Basic and diluted earnings per share for the current period were both ¥0.0104, down from ¥0.0321 in the previous period[31] - The company's actual controller holds 43,342.34 million shares, accounting for 28.75% of the total share capital[24] Liabilities and Equity - Total liabilities rose from ¥1,002,085,571.44 to ¥1,059,307,345.85, marking an increase of approximately 5.7%[28] - The total equity attributable to the parent company increased from ¥1,328,376,939.84 to ¥1,343,688,806.49, a rise of approximately 1.2%[28] Investment and Other Income - Investment income surged by 642.68% to ¥27,908,942, primarily due to the turnaround in performance of a joint venture[8] - The company reported a significant increase in investment income, reaching ¥27,908,942.16 compared to ¥3,757,848.68 in the previous period[30] Operational Changes and Legal Matters - The company has initiated arbitration against Andermatt for unpaid transfer payments totaling CNY 46.92 million[13] - The arbitration court ruled that Andermatt must pay the company a total of CNY 45.62 million, including various delayed payments and related fees[14] - As of the financial report approval date, the company has not received the delayed payment amounts[15] - The company is in the process of closing its subsidiary, Jiangsu Kofit, as it was listed as a company to be closed in 2022[21] - Jianglong Chemical Company was declared bankrupt by the court in June 2024, and its operations were terminated in 2023[22] - Zhicheng Chemical Company has completed tax and bank account cancellation procedures and is no longer included in the consolidated financial statements[22] Changes in Assets - Accounts receivable decreased from ¥81,238,491.24 to ¥45,672,368.19, indicating a reduction of approximately 43.7%[27] - Inventory increased from ¥57,481,221.30 to ¥64,907,635.68, reflecting a growth of about 12.5%[27] - The company reported a significant increase in prepayments, which rose by 174.03% to ¥97,479,097, attributed to increased trade business[8] Management Expenses - The company experienced a decrease in management expenses to ¥14,118,649.46 from ¥18,554,689.12 in the previous period, a reduction of 24.8%[30] Comprehensive Income - Other comprehensive income after tax for the current period was -¥618,117.69, compared to -¥294,413.85 in the previous period[31]

Financial Performance - The company's operating revenue for 2024 was CNY 280,010,549.43, representing a 21.16% increase compared to CNY 231,110,967.07 in 2023[21] - The net profit attributable to shareholders for 2024 was a loss of CNY 155,094,732.30, an improvement of 66.81% from a loss of CNY 467,326,866.73 in 2023[21] - The net cash flow from operating activities for 2024 was a negative CNY 41,466,656.39, which is a decline of 94.73% compared to a negative CNY 21,294,730.57 in 2023[21] - The total assets at the end of 2024 were CNY 2,274,291,204.20, down 17.28% from CNY 2,749,455,376.71 at the end of 2023[21] - The net assets attributable to shareholders decreased by 10.63% to CNY 1,328,376,939.84 at the end of 2024 from CNY 1,486,372,364.45 at the end of 2023[21] - The basic earnings per share for 2024 were CNY -0.10, an improvement of 67.74% from CNY -0.31 in 2023[21] - The company reported a significant reduction in non-recurring losses, with the net profit excluding non-recurring items improving by 45.50% to CNY -233,850,049.25 in 2024 from CNY -429,075,845.95 in 2023[21] Revenue Breakdown - The company's total revenue for Q4 2024 reached ¥126,452,138.91, a significant increase compared to Q3 2024's ¥43,442,264.59[26] - The revenue from the pesticide and intermediates segment was ¥139,477,845.34, accounting for 49.81% of total revenue, with a year-on-year growth of 21.31%[50] - The revenue from direct sales was ¥141,818,254.55, which is 50.65% of total revenue, reflecting a year-on-year increase of 22.02%[50] - The overseas revenue surged to ¥31,903,739.40, a staggering increase of 1,292.75% from ¥2,290,706.65 in the previous year[50] Costs and Expenses - The total operating costs for 2024 were ¥252,097,873.00, representing a 55.55% increase compared to ¥162,064,454.00 in 2023[57] - The average energy procurement price constitutes over 30% of total production costs, indicating a critical area for cost management[38] Business Transformation and Strategy - The company has undergone a business transformation since 2021, focusing on the development and sales of pesticide formulations and e-commerce in agricultural products[20] - The strategic focus on "soil health, crop health, and human health" underpins the company's brand positioning and innovation efforts[44] - The company is focusing on technology innovation and ecological co-construction in its petrochemical supply chain segment[48] - The company plans to advance its petrochemical supply chain and ammonia-hydrogen new energy business, with a new liquid ammonia low-temperature tank project expected to reach a storage and transportation capacity of 1 million tons[89] Research and Development - The company has developed innovative products using thiamethoxam and other compounds, with 18 invention patents applied and 11 granted domestically, focusing on over 40 agricultural countries along the Belt and Road Initiative[40] - The proprietary subcritical small molecule technology has resulted in 23 patents and will establish the first industrialized production line in 2024, generating significant industry attention[40] - Research and development expenses decreased by 27.75% to ¥1,526,224.42, representing 0.55% of operating revenue, down from 1.37% in the previous year[64] Corporate Governance - The company has established a value management system and disclosed a valuation enhancement plan[94] - The company has maintained strict compliance with information disclosure regulations, ensuring timely and accurate communication with investors[102] - The company operates independently from its controlling shareholders in terms of business, assets, and personnel[105] - The company has a clear organizational structure, with no interference from major shareholders in operational activities[106] Legal and Compliance Issues - The company faced ongoing disputes related to its investment in Ruikai Company, which affected the ability to measure the fair value of the investment, resulting in a recognized loss of approximately 62.43 million yuan[158] - There are multiple pending lawsuits that may significantly impact the company's future operations, with new cases added post-reporting period[159] - The company has been fined a total of 31,000 yuan for promotional violations across different entities[175] Employee and Management Information - The total number of employees at the end of the reporting period is 340, with 61 in the parent company and 279 in major subsidiaries[128] - The company has established a competitive compensation and benefits system to attract and retain talent, based on job responsibilities and performance[130] - The company has implemented an employee stock ownership plan, which effectively aligns the interests of employees, the company, and society[136] Internal Control and Audit - The internal control system has been updated and improved, with no significant deficiencies reported during the reporting period[137] - The audit report emphasizes that there is a deviation between the actual revenue after deductions and the forecast, indicating a need for improved information disclosure[147] - The company has established and implemented internal controls in accordance with the basic norms of internal control[143] Environmental and Social Responsibility - There were no significant environmental violations or administrative penalties reported during the period, and subsidiaries have ceased operations with no pollution discharge[151] - The company has committed to social responsibility initiatives, actively participating in charitable activities and promoting social progress[152]

证券代码：002496 证券简称：辉丰股份 公告编号：2025-011 江苏辉丰生物农业股份有限公司 关于自愿披露全资子公司获得成品油经营资质的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 三、相关风险提示 辉丰石化本次获准增加的成品油经营许可，后续经营对公司的收入和利润的 影响尚存在不确定性。请投资者审慎决策，注意投资风险。 四、备查文件 1、《危险化学品经营许可证》 特此公告。 江苏辉丰生物农业股份有限公司董事会 一、基本情况 江苏辉丰生物农业股份有限公司（下简称"公司"）全资子公司江苏辉丰石 化有限公司（下简称"辉丰石化"）于今日取得盐城市应急管理局新颁发的《危 险化学品经营许可证》，增加了"成品油：汽油、柴油、煤油"的经营许可范围。 二、对公司的影响 辉丰石化本次获准成品油：汽油、柴油、煤油的经营许可，辉丰石化将可结 合现有罐区资源，开展成品油的自主经营，有助于公司的长期经营发展。 二〇二五年四月十八日 ...

会计师初步审计 2024 年度的净利润为负值且扣除后营业收入存在低于 3 亿 元的可能，具体内容详见公司已披露的《2024 年度业绩预告》（公告编号： 2025-001）。 证券代码：002496 证券简称：辉丰股份 公告编号：2025-010 江苏辉丰生物农业股份有限公司 关于公司股票交易可能被实施退市风险警示的 第三次风险提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 公司于 2025 年 1 月 23 日对公司股票交易可能被实施退市风险警示事项进行 了首次提示，于 2025 年 4 月 8 日进行了第二次风险提示。本次公告为第三次风 险提示，敬请广大投资者注意投资风险。 一、公司股票交易可能被实施退市风险警示的原因 公司 2024 年年度报告披露后，如果最近一个会计年度经审计的净利润为负 值且扣除后营业收入低于 3 亿元，根据《深圳证券交易所股票上市规则》第 9.3.1 条规定，公司股票交易将被实施退市风险警示（股票简称前冠以"*ST"字样）。 二、风险提示及其他事项 1、最终财务数据以公司正式披露的经审计后的 2024 年年 ...